ClinicalTrials.gg
CompletedNCT05231746Updated Mar 13, 2024

A Study of hSTC810 With Advanced/Metastatic Solid Tumors (STCUBE-001)

A Phase 1 interventional study of hSTC810 in Advanced Solid Tumor, sponsored by STCube, Inc.. Completed at 5 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-13.

Sponsored by STCube, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Feb 2024, 2 years 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
47
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 2,339 studies in Colorectal Neoplasms with a site in United States — 418 open to participants now, 630 under way, 30 of them phase 3. Colorectal Neoplasms · United States.

Enrollment
1,137th of 1,932
47 · median 64
Started
2022
with 126 others
Phase 1
551 of 2,339
100 open now
Registered
1,715th of 2,339
by date

Among the 2,339 studies in Colorectal Neoplasms with a site in United States, this one is the 1,137th largest by enrollment of the 1,932 interventional ones that give a count, is one of 127 that started in 2022, is one of 551 in phase 1, and was the 1,715th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

418 of the 2,339 studies in Colorectal Neoplasms with a site in United States are open now. Recruiting first, the newest first:

413 more — sign in →

All 418 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,339 studies in Colorectal Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The Purpose of this study is to investigate the safety, tolerability, pharmacokinetics, and preliminary efficacy of hSTC810 monotherapy in participants with advanced solid tumors.

Read the detailed description

The study consists of a dose-escalation phase that will evaluate 6 dosing schedules of hSTC810. The first cohort will be single participant cohort. Subsequent escalation cohorts will use a standard 3+3 design, with the ability to backfill up to an additional 6 patients in each dose cohort.

03

Conditions studied

  • Advanced Solid Tumor

Keywords

  • Immune Checkpoint Inhibitors
  • Antineoplastic Agents
  • Therapeutic Uses
  • Colorectal Neoplasms
  • Head and Neck Neoplasms
  • Ovarian Neoplasms
  • Urinary Bladder Neoplasms
  • Lung Neoplasms
  • Antibodies, Monoclonal
  • anti-BTN1A1
  • butyrophilins
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female aged at 18 ≥ years
  • Capable and willing to give signed
  • At least one as determined by Ver.1.1
  • PS score ≤ 1
  • Expected survival ≥ 12 weeks
  • For female or male patients of : Agree to use throughout the study and at least 6 months after the last dose.

Exclusion criteria

Exclusion Criteria:

  • Subject who has received anti-cancer treatment within 4 weeks prior to the first dose of study treatment.
  • Subject who has received radiotherapy or major surgery within 4 weeks prior to screening.
  • Any toxicity due to prior therapy that has not resolved to ≤ Grade 1 or returned to baseline by the time of starting study treatment.
  • Subject with known severe (≥Grade 3) to any .
  • laboratory abnormalities.
  • Subject with a history of another invasive within 3 years before the first dose of study drug.
  • Subject with active central nervous system (CNS) .
  • Subject who requires high dose of or other medications.
  • Subject with a history of disease that has required systemic treatment in the past 2 years.
  • Subject with active infection that requires systemic antimicrobial treatment.
  • Subject with active or infection.
  • Subject who has a known history of infection.
  • Subject with active tuberculosis.
  • Subject with a documented history of a cerebral vascular event, unstable angina, myocardial infarction, or cardiac symptoms consistent with Class IV within 6 months prior to screening.
  • Subject with a history of idiopathic pulmonary fibrosis, organizing pneumonia, drug induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening CT scan.
  • Subject who has received a prior allogeneic stem cell or solid organ transplant.
  • Subject with a positive coronavirus disease (COVID) test during screening.
  • Subjects who have received a within 30 days prior to screening.
  • Subject with another underlying medical condition.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
47 participants (actual)

Study arms

  • Experimental
    hSTC810

    6 escalating doses of hSTC810 will be administered to participants

    Biological: hSTC810

Interventions

  • BiologicalhSTC810

    hSTC810 will be administered as an intravenous infusion (IV)

06

What researchers measure

Primary outcomes

  1. Incidence of DLTs

    Number and percentages of subjects with DLTs

    Time frame: 4 weeks

  2. Incidence of AEs, SAEs, and abnormalities in Lab

    Number and percentages of subjects with Adverse Event, serious AEs, and abnormalities in lab parameters

    Time frame: from signing ICF to 90 days after last dose

Secondary outcomes

  1. Peak plasma concentration (Cmax)

    Maximum plasma concentration of hSTC810 to evaluate the PK parameters

    Time frame: Up to 2 years

  2. Minimum plasma concentration (Cmin)

    Minimum blood plasma concentration of hSTC810 to evaluate the PK parameters

    Time frame: Up to 2 years

  3. Time to maximum plasma concentration (Tmax)

    Time to reach Cmax of hSTC810 to evaluate the PK parameters.

    Time frame: Up to 2 years

  4. Area under the plasma concentration - time curve (AUC0-t)

    AUC up to the last measurable concentration of hSTC810 to evaluate the PK parameters

    Time frame: Up to 2 years

  5. Incidence of ADA

    Number and percentages of subjects with positive ADAs

    Time frame: Up to 2 years

  6. Objective response rate (ORR)

    Percentage of participants with confirmed CR and confirmed PR determined by RECIST v1.1 and iRECIST

    Time frame: Up to 2 years

  7. Best overall response (BOR)

    the best response designation as determined by RECIST and iRECIST. The BOR will be categorized as a CR, PR, SD, or PD

    Time frame: Up to 2 years

  8. Clinical Benefit rate (CBR)

    Percentage of Participants With confirmed CR, confirmed PR or SD with a duration of at least 6 months determined by RECIST v1.1 and iRECIST

    Time frame: Up to 2 years

  9. Duration of response (DoR)

    Time from initial response of confirmed CR or PR to disease progression or death determined by RECIST v1.1 and iRECIST

    Time frame: Up to 2 years

  10. Progression free survival (PFS)

    The period from the first dose to the documented disease progression or death determined by RECIST v1.1 or iRECIST

    Time frame: Up to 2 years

  11. Overall survival (OS)

    The period from first dose to the day of death from any cause.

    Time frame: Up to 2 years

07

Study locations

5 sites
  • Yale Cancer Center
    New Haven, Connecticut 06511, United States
  • Mount Sinai Hospital
    New York, New York 10029, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Korea University Anam Hospital
    Seoul, 02841, Korea, Republic of
  • Yonsei University Severance Hospital
    Seoul, 03722, Korea, Republic of
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2022 to primary completion in Feb 2024, 22 months.

Of 269 industry-sponsored phase 1 interventional studies under Colorectal Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 66. This study's 22 months is below that.

Counting every sponsor, half of 435 studies reached it within 48 months; a quarter within 31 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 25, 2022
First posted
Feb 9, 2022
StartActual
Apr 18, 2022
Primary completionActual
Feb 29, 2024
CompletionActual
Feb 29, 2024
Last update
Mar 13, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05231746
Lead sponsor
STCube, Inc.
Responsible party
Sponsor
First posted
Feb 9, 2022
Start date
Apr 18, 2022
Primary completion
Feb 29, 2024
Completion
Feb 29, 2024
Last update
Mar 13, 2024

Study contacts

Medical director
study director · STCube, Inc.

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nelmastobart

Start the discussion